<p><em>NeoGenomics 正在朝着 2026 年第一季度在美国全面推出其 RaDaR ST 分子残留疾病 (MRD) 检测的目标迈进</em></p>
<p>佛罗里达州迈尔斯堡 --（商业资讯）--NeoGenomics, Inc.（纳斯达克代码：NEO），一家领先的肿瘤诊断解决方案提供商，致力于精准医疗，今天宣布 Natera 自愿撤回其对北卡罗来纳州地区法院 2025 年 8 月裁决的上诉（因此 NeoGenomics 也撤回了其交叉上诉）。该撤回将维持对 NeoGenomics 有利的裁决。</p>
<p>该裁决由北卡罗来纳州中区地区法院作出，批准了 NeoGenomics 的简易判决动议，并裁定 Natera 所主张的专利权利因声称不符合资格的主题而无效。法院以偏见驳回了 Natera 对 NeoGenomics 的指控，并就 Natera 所主张的两项专利作出了无效的声明性判决。</p>
<p>“我们非常高兴 Natera 自愿决定结束这一诉讼过程，” NeoGenomics 首席执行官 Tony Zook 说。“虽然我们对自己的立场充满信心，但这一最新进展使我们能够将全部精力集中在明年第一季度 RaDaR ST 的强劲临床推出上。”</p>
<p><strong>关于 NeoGenomics</strong></p>
<p>NeoGenomics, Inc. 是一家顶尖的癌症诊断公司，专注于癌症遗传学检测和信息服务。我们提供涵盖癌症全周期的最全面的肿瘤学检测菜单之一，为肿瘤科医生、病理学家、医院系统、学术中心和制药公司提供创新的诊断和预测检测，帮助他们诊断和治疗癌症。NeoGenomics 总部位于佛罗里达州迈尔斯堡，在美国运营一网络的 CAP 认证和 CLIA 认证实验室，提供全方位的样本处理和分析服务，并在英国剑桥设有一家 CAP 认证的全方位样本处理实验室。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。这些前瞻性声明通常可以通过使用 “预期”、“期望”、“计划”、“可以”、“可能”、“将”、“相信”、“估计”、“预测”、“目标”、“项目”、“指导”、“潜在” 等词语来识别，尽管并非所有前瞻性声明都包含这些词语。这些前瞻性声明包括关于公司计划在 2026 年第一季度推出 RaDaR ST 分子残留疾病检测的声明。本新闻稿中包含的每一项前瞻性声明都受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。适用的风险和不确定性包括但不限于在公司 10-K 表格年度报告、10-Q 表格季度报告以及公司向证券交易委员会提交的其他文件中列出的 “风险因素” 下识别的风险。</p>
<p>我们提醒投资者不要对本新闻稿中包含的前瞻性声明过于依赖。我们鼓励您阅读我们向 SEC 提交的文件，这些文件可在 www.sec.gov 上找到，并在我们网站的 “投资者” 部分（ir.neogenomics.com）中讨论这些及其他风险和不确定性。本新闻稿中的前瞻性声明仅在本文件日期（除非另有说明）时有效，我们不承担更新或修订这些声明的义务。我们的业务面临重大风险和不确定性，包括上述提到的风险。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTU1MDgzNjByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTU1MDgzNjByMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251215508360/en/</p>
<p><strong>投资者联系</strong></p>
<p>Kendra Webster</p>
<p>InvestorRelations@neogenomics.com</p>
<p><strong>媒体联系</strong></p>
<p>Andrea Sampson</p>
<p>asampson@sampsonprgroup.com</p>
<p>来源：NeoGenomics, Inc.</p>

<p>NeoGenomics 宣布，Natera 已自愿撤回其在进行中的 RaDaR 专利诉讼中的上诉，北卡罗来纳州地方法院对 NeoGenomics 有利的裁决得以维持。此决定使 NeoGenomics 能够专注于在 2026 年第一季度临床推出其 RaDaR ST 分子残留疾病检测。NeoGenomics 是一家领先的肿瘤诊断解决方案提供商，专注于癌症遗传检测和信息服务</p>

<p><em>NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026</em></p>
<div class="lb-trans"><p><em>NeoGenomics 正在朝着 2026 年第一季度在美国全面推出其 RaDaR ST 分子残留疾病 (MRD) 检测的目标迈进</em></p>
</div><p>FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court’s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics’ favor.</p>
<div class="lb-trans"><p>佛罗里达州迈尔斯堡 --（商业资讯）--NeoGenomics, Inc.（纳斯达克代码：NEO），一家领先的肿瘤诊断解决方案提供商，致力于精准医疗，今天宣布 Natera 自愿撤回其对北卡罗来纳州地区法院 2025 年 8 月裁决的上诉（因此 NeoGenomics 也撤回了其交叉上诉）。该撤回将维持对 NeoGenomics 有利的裁决。</p>
</div><p>That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics’ motion for summary judgment and held that Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Court dismissed Natera’s claims against NeoGenomics with prejudice and entered a declaratory judgment of invalidity with respect to both of Natera’s asserted patents.</p>
<div class="lb-trans"><p>该裁决由北卡罗来纳州中区地区法院作出，批准了 NeoGenomics 的简易判决动议，并裁定 Natera 所主张的专利权利因声称不符合资格的主题而无效。法院以偏见驳回了 Natera 对 NeoGenomics 的指控，并就 Natera 所主张的两项专利作出了无效的声明性判决。</p>
</div><p>“We are very pleased that Natera has voluntarily decided to end this litigation process,” said Tony Zook, CEO of NeoGenomics. “While we were confident in our position, this latest development nonetheless allows us to focus our full attention on executing a robust clinical launch of RaDaR ST in the first quarter of next year.”</p>
<div class="lb-trans"><p>“我们非常高兴 Natera 自愿决定结束这一诉讼过程，” NeoGenomics 首席执行官 Tony Zook 说。“虽然我们对自己的立场充满信心，但这一最新进展使我们能够将全部精力集中在明年第一季度 RaDaR ST 的强劲临床推出上。”</p>
</div><p><strong>About NeoGenomics</strong></p>
<div class="lb-trans"><p><strong>关于 NeoGenomics</strong></p>
</div><p>NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.</p>
<div class="lb-trans"><p>NeoGenomics, Inc. 是一家顶尖的癌症诊断公司，专注于癌症遗传学检测和信息服务。我们提供涵盖癌症全周期的最全面的肿瘤学检测菜单之一，为肿瘤科医生、病理学家、医院系统、学术中心和制药公司提供创新的诊断和预测检测，帮助他们诊断和治疗癌症。NeoGenomics 总部位于佛罗里达州迈尔斯堡，在美国运营一网络的 CAP 认证和 CLIA 认证实验室，提供全方位的样本处理和分析服务，并在英国剑桥设有一家 CAP 认证的全方位样本处理实验室。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the Company’s plans to launch its RaDaR ST molecular residual disease assay in the first quarter of 2026. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading &#34;Risk Factors&#34; contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。这些前瞻性声明通常可以通过使用 “预期”、“期望”、“计划”、“可以”、“可能”、“将”、“相信”、“估计”、“预测”、“目标”、“项目”、“指导”、“潜在” 等词语来识别，尽管并非所有前瞻性声明都包含这些词语。这些前瞻性声明包括关于公司计划在 2026 年第一季度推出 RaDaR ST 分子残留疾病检测的声明。本新闻稿中包含的每一项前瞻性声明都受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。适用的风险和不确定性包括但不限于在公司 10-K 表格年度报告、10-Q 表格季度报告以及公司向证券交易委员会提交的其他文件中列出的 “风险因素” 下识别的风险。</p>
</div><p>We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>
<div class="lb-trans"><p>我们提醒投资者不要对本新闻稿中包含的前瞻性声明过于依赖。我们鼓励您阅读我们向 SEC 提交的文件，这些文件可在 www.sec.gov 上找到，并在我们网站的 “投资者” 部分（ir.neogenomics.com）中讨论这些及其他风险和不确定性。本新闻稿中的前瞻性声明仅在本文件日期（除非另有说明）时有效，我们不承担更新或修订这些声明的义务。我们的业务面临重大风险和不确定性，包括上述提到的风险。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTU1MDgzNjByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251215508360r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251215508360/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251215508360/en/</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>Kendra Webster</p>
<div class="lb-trans"><p>Kendra Webster</p>
</div><p>InvestorRelations@neogenomics.com</p>
<div class="lb-trans"><p>InvestorRelations@neogenomics.com</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系</strong></p>
</div><p>Andrea Sampson</p>
<div class="lb-trans"><p>Andrea Sampson</p>
</div><p>asampson@sampsonprgroup.com</p>
<div class="lb-trans"><p>asampson@sampsonprgroup.com</p>
</div><p>Source: NeoGenomics, Inc.</p>
<div class="lb-trans"><p>来源：NeoGenomics, Inc.</p>
</div>

NeoGenomics 宣布 Natera 已自愿撤回其在持续进行的 RaDaR 专利诉讼中的上诉 | NEO 股票新闻